This startup develops therapies specifically designed to prevent postoperative atrial fibrillation through targeted interventions. By addressing the high incidence of this condition in surgical patients, the company aims to improve recovery outcomes and reduce healthcare costs associated with atrial fibrillation complications.
Funding
$340K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Atrial fibrillation, the most common cardiac arrhythmia, affects millions globally and currently lacks a cure, with existing treatments only managing symptoms rather than addressing the underlying physiological causes. Postoperative atrial fibrillation (POAF) is a frequent complication following open-chest surgery, leading to increased morbidity and healthcare costs.
Solution
Rhythm Biotherapeutics is developing exosome-based therapies to prevent and treat atrial fibrillation by targeting the root causes of the condition. Their lead candidate, RBex, is a prophylactic exosome therapy focused on preventing postoperative atrial fibrillation (POAF). Preclinical studies have demonstrated an 87% reduction in POAF with RBex, which uniquely addresses atrial inflammation and fibrosis, the fundamental physiological mechanisms driving POAF. The company is advancing towards first-in-human phase 1 clinical trials.
Target Audience
The primary target audience includes patients undergoing open-chest cardiac surgery at risk of developing postoperative atrial fibrillation, as well as those with paroxysmal and persistent atrial fibrillation.
Features
- Prophylactic exosome therapy to prevent postoperative atrial fibrillation (POAF)
- Targets atrial inflammation and fibrosis, the underlying causes of atrial fibrillation
- Demonstrated 87% reduction in POAF in preclinical studies
- Utilizes human cardiac exosomes
- Pipeline includes treatments for paroxysmal and persistent atrial fibrillation